Research Information System
Progres en Urologie, vol.33, no.11, pp.555-561, 2023 (SCI-Expanded, Scopus)
Background: We aimed to examine the oral and topical effect of Oltipraz (OPZ) on fibrosis and healing after urethra injury in a rat model. Methods: In all, 33 adult Sprague-Dawley rats were divided randomly into 5 different groups: sham, urethral injury group (UI), oral Oltipraz treatment group for 14 days after urethral injury (UI + oOPZ), intraurethral Oltipraz treatment group for 14 days after urethral injury (UI + iOPZ) and only intraurethral Oltipraz treatment for 14 days without urethral injury (sham + iOPZ). Pediatric urethrotome blade was used to create the urethral injury model for the injury groups (UI, UI + oOPZ and UI + iOPZ). After 14 days of treatment, all rats were sacrificed after penectomy under general anesthesia. Urethral tissue was evaluated histopathologically for congestion, inflammatory cell infiltration and spongiofibrosis, and immunohistochemically for transforming growth factor Beta-1 (TBF) and vascular endothelial growth factor receptor2 (VEGFR2). Results: The congestion score was not statistically significantly different between the groups. Spongiofibrosis was distinctive in UI group and OPZ given groups. Inflammation and spongiofibrosis score were statistically significantly higher in the sham + iOPZ group compared to the sham group (P < 0.05). VEGFR2 and TGF Beta-1 scores were statistically significantly higher in the sham + iOPZ group compared to the sham group (P < 0.05). We did not find beneficial effect of OPZ on urethral healing. We found the harmful effect of intraurethral administration of OPZ in the group without urethral injury in compared to sham. Conclusions: According to our results, we cannot suggest OPZ in the treatment of urethral injury. Future studies in this area are needed.